BMS Signs a Clinical Trial Collaboration with UbiVac to Evaluate the Triplet Therapy for Advanced Triple Negative Breast Cancer

 BMS Signs a Clinical Trial Collaboration with UbiVac to Evaluate the Triplet Therapy for Advanced Triple Negative Breast Cancer

BMS Signs a Clinical Trial Collaboration with UbiVac to Evaluate the Triplet Therapy for Advanced Triple Negative Breast Cancer

Shots:

  • The two companies collaborated to evaluate the safety, tolerability, and preliminary efficacy of UbiVac’s DPV-00 in combination with BMS’ anti-OX40 (BMS-986178) combined with Opdivo (nivolumab)
  • The P-Ib study will test the hypothesis that combination immunotherapy with the DPV-001 vaccine and anti-OX40 will boost anticancer immunity in patients with advanced TNBC
  • UbiVac’s DRibble Platform Vaccine, DPV-001 contains 100+ proteins overexpressed by the average TNBC and as many as 1,700 altered peptide ligands that can enhance immunity against cancer antigens

Click here to read full press release/ article | Ref: BuinessWire | Image: UbiVac

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post